ET
VRTX icon

Equitable Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Equitable Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-512
Closed -$254K – 463
2026
Q2 		$254K Sell
512
-50
-9% -$22.2K 0.01% 421
2026
Q1 		$251K Buy
562
+66
+13% +$30.8K 0.01% 430
2025
Q4 		$225K Buy
+496
New +$214K 0.01% 421
2025
Q2 		– Sell
-521
Closed -$253K – 472
2025
Q1 		$253K Hold
521
– – 0.01% 428
2024
Q4 		$210K Sell
521
-3
-0.6% -$1.39K 0.01% 458
2024
Q3 		$244K Buy
+524
New +$252K 0.02% 418

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Gateway Investment Advisers
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Equitable Trust's VRTX Position: Q3 2026 in Review

Equitable Trust sold out of Vertex Pharmaceuticals (VRTX) in Q3 2026, closing a stake of 512 shares — an estimated $254K sold.

Equitable Trust first reported a position in VRTX in Q3 2024 and held it in 6 quarters. The position peaked at $254K in Q2 2026. 278 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Equitable Trust reported no remaining Vertex Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Equitable Trust sold 512 Vertex Pharmaceuticals shares in Q3 2026, an estimated $254K.
  • Equitable Trust first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Equitable Trust's Vertex Pharmaceuticals position peaked at $254K in Q2 2026.
  • 278 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Equitable Trust's 13F filing for Q3 2026, filed 13 Oct 2026.